PRESS RELEASE
December 2[nd],[ ]2020
Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)
Viewers will learn how Nanoform's award-winning CESS[® ]nanoparticle engineering technology can potentially double the number of drug candidates progressing into clinic. The use of Nanoform's unique process to open up new drug delivery routes and improve the lives of patients worldwide will also be explored.
The TV feature represents a valuable opportunity for Nanoform to increase awareness of its technology globally. Following its broadcast, the episode will be available for on-demand viewing on Amazon Prime Video. On
Prof. Edward Hæggström, Nanoform CEO, commented "Innovation has real impact when people know about it, and we are thrilled to partner with Advancements to show the power of our technology to the public. Our driving force is to provide hope for patients by helping novel drugs progress to the market, and this feature will bring that vision to TV screens across the
For further information, please contact:
Prof. Edward Hæggström, CEO
edward.haeggstrom@nanoform.com / +358 29 370 0150
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/nanoform-makes-us-tv-debut-in-advancements-with-ted-danson--cnbc-,c3247730
https://mb.cision.com/Main/18905/3247730/1343091.pdf
(c) 2020 Cision. All rights reserved., source